[Featured Stock] IMBDX, Proven Efficacy and Commercialization Expected... One Step Closer to Cancer Conquest

IMBDX is showing strong performance. The news that AlphaLiquid®100 has proven useful for personalized treatment of lung cancer patients appears to be influencing the stock price.

As of 1:58 PM on the 27th, IMBDX is trading at 21,600 KRW, up 2.61% from the previous day.

IMBDX is a global healthcare company challenging cancer conquest by enabling patient-tailored precision medicine and early diagnosis throughout the entire cancer development cycle based on innovative liquid biopsy technology. Its services are composed of three areas: precision diagnosis and treatment of advanced cancer, early detection of recurrence after surgery, and early cancer diagnosis. The company has secured and commercialized all technologies applicable throughout the cancer development cycle, including profiling technology for advanced cancer patients, detection technology for early recurrence diagnosis after surgery for stages 1 to 3 cancer, and screening technology to detect cancer early and predict the primary site.

On this day, the precision medicine company IMBDX announced that through recent collaborative research with Taiwan, it has proven that pleural effusion testing using AlphaLiquid®100 is useful for personalized treatment of lung cancer patients.

In the analysis of pleural effusion (PE) samples from non-small cell lung cancer patients using AlphaLiquid®100, major gene mutations such as epidermal growth factor receptor (EGFR) were observed in 92.3% of cases. It was explained that patients with EGFR mutations all showed partial response within three months after EGFR inhibitor treatment.

About 15% of lung cancer patients have malignant pleural effusion at diagnosis, and more than 50% of patients develop malignant pleural effusion during treatment. However, in the past, detecting gene mutations through pleural effusion was difficult, but with the liquid biopsy technology using AlphaLiquid®100, gene mutations such as EGFR can now be effectively detected in pleural effusion. This technology is expected to be superior to tissue samples in detecting gene mutations.

Professor Chang of Far Eastern Memorial Hospital (FEMH) in Taiwan, who led the research, stated, "The joint research results with IMBDX highlight the importance of liquid biopsy in various specimens including pleural effusion," adding, "It enables the establishment of more precise treatment strategies for lung cancer."

IMBDX CEO Kim Tae-yu said, "The AlphaLiquid®100 test enables personalized treatment not only from cancer patients' blood but also from various specimens such as pleural effusion, urine, and cerebrospinal fluid," emphasizing, "Regulatory relaxation is needed so that liquid biopsy can be more actively utilized in clinical practice."

IMBDX currently provides services for various specimens including blood, cerebrospinal fluid, pleural effusion, ascites, and tissue in overseas markets. Domestically, it is expanding collaboration with domestic panel testing institutions to provide innovative solutions in the field of genomic analysis based on liquid biopsy technology.

AlphaLiquid®100 is a hybrid capture-based NGS panel that can analyze gene mutations in 118 major cancer-related genes. Using 10 mL of blood, it analyzes tumor-derived gene mutations to select personalized targeted therapies. It is used for monitoring treatment effects and discovering gene mutations related to anticancer drug resistance.

Researcher Kang Si-on of Korea Investment & Securities analyzed, "IMBDX's flagship product is AlphaLiquid100 for patients with stage 3 to 4 solid tumors," adding, "Sales in Thailand are steady following Taiwan, and market entry into Japan and India is expected to materialize in the second half of this year."

CancerDetect is also generating growing expectations for commercialization within the year. CancerDetect is a product that detects ultra-low levels of ctDNA remaining after surgery and was the first of its kind developed domestically. Globally, it is the third product developed based on tissue-derived capture panels.

Researcher Heo Seon-jae of SK Securities stated, "On the 20th, an application for innovative medical technology evaluation was submitted for the CancerDetect (recurrence monitoring) product," adding, "Submitting an innovative medical technology evaluation means that the commercialization of the CancerDetect product, which was previously used only for research, is imminent." He further added, "It is expected to enter the medical market in a non-reimbursed form by the end of the year at the latest," and "It will emerge as a game changer in the cancer recurrence treatment market."